Table 1.
Baseline characteristics of subjects
| (a) n = 320 | (b) n = 878 | P value | ||
|---|---|---|---|---|
| Age (mean ± SD) | 63.3 ± 9.3 | 64.6 ± 8.8 | 0.025* | |
| Gender | M/F | 211/109 | 594/284 | 0.952 |
| Etiology (%) | HCV | 71.9 | 69.5 | 0.101 |
| HBV | 19.0 | 17.0 | ||
| HBV + HCV | 4.5 | 5.2 | ||
| Alcohol | 2.9 | 3.2 | ||
| Others | 1.6 | 5.1 | ||
| Number of treatments (median) | 2.0 (1–14) | |||
| Tumor size (mm) (median) | 30.0 (8–190) | 25.0 (5–190) | 0.001* | |
| Number of tumors (%) | 1 | 59.1 | 44.0 | 0.061 |
| 2, 3 | 29.2 | 30.3 | ||
| 4, 5 | 5.0 | 7.4 | ||
| > 5 | 6.6 | 18.4 | ||
| Vascular invasion | Yes/No | 26/294 | 74/804 | 0.983 |
| Child-Pugh class (%) | A | 69.7 | 68.6 | 0.875 |
| B | 28.8 | 29.5 | ||
| C | 1.6 | 1.9 | ||
| Median survival time (months) | 56.8 (2.5–157.1) | 37.4 (1.0–157.1) | <0.0001* | |
| Alpha-fetoprotein (ng/dl) (median) | 46.6 (0–106) | 61.6 (0–106) | 0.059 | |
| DCP (AU/L) (median) | 19.0 (0–193,000) | 26.0 (0–193,000) | 0.140 | |
| Total bilirubin (mg/dl) | 1.3 ± 0.6 | 1.3 ± 1.1 | 0.187 | |
| Serum albumin (mg/dl) | 3.6 ± 0.6 | 3.6 ± 0.6 | 0.922 | |
| Prothrombin activity (%) | 79.1 ± 16.5 | 79.6 ± 30.9 | 0.757 | |
| ICG R15 (%) | 26.1 ± 14.5 | 27.4 ± 15.3 | 0.194 | |
| Aspartate aminotransaminase (IU/dl) | 79.7 ± 45.5 | 76.8 ± 45.0 | 0.331 | |
| Alanine aminotransferase (IU/dl) | 71.8 ± 46.2 | 66.4 ± 45.8 | 0.070 | |
| Platelet count (104/mm3) | 11.2 ± 5.9 | 10.5 ± 5.8 | 0.155 | |
| Alkaline phosphatase (IU/dl) | 291 ± 177 | 307 ± 172 | 0.147 | |
Note: (a) Subjects who received the initial treatments for the first occurrence of HCC. (b) Total subjects. Values are mean ± standard deviation
Abbreviations: DCP: des-gamma carboxy prothrombin; ICG R15: retention of indocyanine green at 15 min
*P < 0.05